Free Newsletter
SPOTLIGHT: PerkinElmer paying $300M for ViaCell
Free newsletter via e-mail
Tools
PerkinElmer is buying ViaCell for $300 million, aiming to grow the latter's cord-blood banking business and spin off its drug-discovery unit, which is working on stem-cell-based remedies for cancer, heart disease, and diabetes. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: